|Videos|December 20, 2022
Eligibility for Cisplatin Therapy in Patients with MIBC
Author(s)Terence Friedlander, MD
Dr Terence Friedlander defines cisplatin eligibility in patients with MIBC and discusses how many patients receive neoadjuvant cisplatin and the treatment approaches if a patient is ineligible.
Advertisement
Episodes in this series
Advertisement
Related to this article
A survey of US veterans with non-muscle invasive bladder cancer identifies barriers to treatment access, care coordination challenges, and gaps in patient education.
The perioperative regimen improved event-free and overall survival in the phase 3 VOLGA trial, offering a new option for patients with muscle-invasive bladder cancer who cannot receive or decline cisplatin.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
2
New ACS Guidelines Push for Earlier Prostate Cancer Screening
3
Survey Highlights NMIBC Care Challenges Among US Military Service, Veterans
4
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
5